팬젠 둜고

팬젠 (222110) μ£Όκ°€ 및 μ’…λͺ© 정보

팬젠 μ‹€μ‹œκ°„ μ£Όκ°€

팬젠 ν˜„μž¬κ°€ 상세 정보
ν•­λͺ© κ°’
ν˜„μž¬κ°€ 6,050 원
λ³€λ™λŸ‰ β–² 70.00 원
변동λ₯  1.17%
κ±°λž˜λŸ‰ 13,846
κ±°λž˜λŒ€κΈˆ 82,231,150 원

팬젠 일별 μ£Όκ°€

팬젠의 κ³Όκ±° 일별 μ£Όκ°€
λ‚ μ§œ μ‹œκ°€ κ³ κ°€ μ €κ°€ μ’…κ°€ κ±°λž˜λŸ‰ κ±°λž˜λŒ€κΈˆ
8/17/2025 6,030 6,140 5,800 5,810 18,352 108,242,150
8/18/2025 5,920 5,920 5,700 5,730 14,520 83,590,130
8/19/2025 5,640 5,800 5,590 5,710 17,248 97,659,570
8/20/2025 5,710 6,040 5,700 5,940 12,146 71,906,150
8/21/2025 5,940 6,060 5,880 5,980 10,848 64,945,325
8/24/2025 6,030 6,060 5,870 5,950 9,854 58,416,905
8/25/2025 5,960 6,000 5,880 5,950 6,137 36,446,740
8/26/2025 5,950 6,060 5,810 6,040 12,299 72,483,380
8/27/2025 6,050 6,100 5,870 5,980 15,802 94,340,800
8/28/2025 5,930 6,080 5,830 6,050 13,846 82,231,150

κ΄€λ ¨ ν…Œλ§ˆ

  • λ°”μ΄μ˜€μ‹œλ°€λŸ¬ : λ°”μ΄μ˜€μ‹œλ°€λŸ¬ μ˜μ•½ν’ˆ 개발, 제쑰 μ—…μ²΄λ‘œ λ°”μ΄μ˜€μ‹œλ°€λŸ¬ μ˜μ•½ν’ˆμ€ EPO(빈혈 치료제), Factor VIII(ν˜ˆμš°λ³‘A 치료제) 및 G-CSF(ν•­μ•”μΉ˜λ£Œ 보쑰제) μ œν’ˆμ„ 순차적으둜 개발 쀑
  • 혈μž₯치료 : ν˜ˆμš°λ³‘ μΉ˜λ£Œμ œμ™€ λ‹€μ–‘ν•œ ν˜ˆμ•‘ κ΄€λ ¨ 치료제λ₯Ό κ°œλ°œν•΄ 혈μž₯ 치료 관련주에 νŽΈμž…

팬젠 νšŒμ‚¬ 정보

μ‹œμž₯ μ‹œκ°€μ΄μ•‘ κΈ°μ—…μˆœμœ„ μ£Όμ‹μˆ˜ 외ꡭ인 비쀑 μ‚°μ—…κ΅° μ„ΈλΆ€ μ‚°μ—…κ΅° 52μ£Ό 졜고 52μ£Ό μ΅œμ €
kosdaq 816μ–΅ 939μœ„ 13,494,197 7.20% ν—¬μŠ€μΌ€μ–΄ 생λͺ…κ³Όν•™/곡학 7,770 3,810

팬젠 κΈ°μ—… κ°œμš”

νŒ¬μ  μ€ 2010λ…„ 1μ›” μ„€λ¦½λœ κΈ°μ—…μœΌλ‘œ λ°”μ΄μ˜€μ‹œλ°€λŸ¬ EPO μ˜μ•½ν’ˆμ˜ 생산 및 판맀, λ°”μ΄μ˜€μ˜μ•½ν’ˆ 개발, λ°”μ΄μ˜€μ˜μ•½ν’ˆ μœ„νƒμƒμ‚° 및 개발기술 μ΄μ „μ„œλΉ„μŠ€ λ“±μ˜ 사업을 μ˜μœ„ν•˜κ³  μžˆλ‹€. μ£Όμš” λ§€μΆœμ€ EPO μ˜μ•½ν’ˆ νŒλ§€μ—μ„œ λ°œμƒν•˜κ³  μžˆλ‹€. λ‹Ήμ‚¬λŠ” λ§Œμ„± μ‹ λΆ€μ „ ν™˜μžμ˜ 빈혈 치료제인 λ°”μ΄μ˜€μ‹œλ°€λŸ¬ EPO μ˜μ•½ν’ˆ 자체 μ œν’ˆκ°œλ°œμ— μ„±κ³΅ν•˜μ—¬ κ΅­λ‚΄ 및 λ§λ ˆμ΄μ‹œμ•„ μ‹œμž₯μ—μ„œ 판맀 쀑에 있으며 κ·Έ 밖에 λ‹€μ–‘ν•œ λ°”μ΄μ˜€ μ˜μ•½ν’ˆμ„ 개발 쀑에 μžˆλ‹€.

μ΅œμ‹  팬젠 κ΄€λ ¨ λ‰΄μŠ€

[νŒŒμ΄λ‚Έμ…œλ‰΄μŠ€] μ§€μ—˜λ¦¬μ„œμΉ˜λŠ” νœ΄μ˜¨μŠ€μ— λŒ€ν•΄ λ―Έκ΅­ 수좜 ν™•λŒ€μ™€ 제천 2곡μž₯ CAPA ν™•μΆ© λ“±μœΌλ‘œ μ„±μž₯μ„Έκ°€ μ΄μ–΄μ§ˆ 것이라고 21일 λΆ„μ„ν–ˆλ‹€. νœ΄μ˜¨μŠ€λŠ” μ „λ¬Έμ˜μ•½ν’ˆ, CMO, 건강기λŠ₯μ‹ν’ˆ, λ°”μ΄μ˜€ λ“± λ‹€κ°ν™”λœ 포트폴리였λ₯Ό 기반으둜 κ΅­λ‚΄μ™Έ 사업을 μ „κ°œν•˜λŠ” μ œμ•½μ‚¬λ‹€. 이 νšŒμ‚¬μ˜ 올 2λΆ„κΈ° 싀적은 λ§€μΆœμ•‘ 1560얡원(+4.7% YoY), μ˜μ—…μ΄μ΅ 131얡원(+40.3% YoY), 순이읡 118얡원(+46.5% YoY)으둜 λΆ„κΈ° μ΅œλŒ€ λ§€μΆœμ„ κΈ°λ‘ν–ˆλ‹€. λ°•μ°½μœ€ μ§€μ—˜λ¦¬μ„œμΉ˜ 연ꡬ원은 β€œFDA ν—ˆκ°€ ν’ˆλͺ©μ„ 기반으둜 ν•œ λ―Έκ΅­ μ‹œμž₯ 수좜이 λ³Έκ²©ν™”λ˜κ³  있으며, 치과용 마취제 등둝 ν™•λŒ€μ— 따라 μˆ˜μ΅μ„± κ°œμ„  νš¨κ³Όκ°€ κΈ°λŒ€λœλ‹€β€λ©° β€œμ œμ²œ 2곡μž₯의 μ μ•ˆμ œΒ·μ£Όμ‚¬μ œ 생산라인 가동이 ν™•λŒ€λ˜λ©΄μ„œ μ™Έν˜• μ„±μž₯κ³Ό μˆ˜μ΅μ„± κ°œμ„ μ΄ λ™μ‹œμ— κ°€λŠ₯ν•΄μ§ˆ 것”이라고 λ‚΄λ‹€λ΄€λ‹€. κ·ΈλŸ¬λ©΄μ„œ β€œκ±΄κ°•κΈ°λŠ₯μ‹ν’ˆ 사업뢀 뢄할합병 효과둜 μ—°

올 2λΆ„κΈ° μ—­λŒ€ μ΅œλŒ€ λΆ„κΈ° λ§€μΆœμ„ λ‹¬μ„±ν•œ 휴온슀의 μ„±μž₯μ„Έκ°€ 지속될 κ²ƒμ΄λΌλŠ” 전망이 λ‚˜μ™”λ‹€. μ§€μ—˜λ¦¬μ„œμΉ˜λŠ” λ―Έκ΅­ 수좜 ν™•λŒ€μ™€ 제천 2곡μž₯ 생산λŠ₯λ ₯(CAPA) ν™•μΆ© λ“±μœΌλ‘œ 휴온슀의 μ„±μž₯μ„Έκ°€ μ΄μ–΄μ§ˆ 것이라고 λΆ„μ„ν•œ 리포트λ₯Ό 21일 λ°œν–‰ν–ˆλ‹€.휴온슀 μ„±μž₯동λ ₯의 핡심은 λ―Έκ΅­ μ‹œμž₯

νœ΄μ˜¨μŠ€κΈ€λ‘œλ²Œ(λŒ€ν‘œ μœ€μ„±νƒœΒ·μ†‘μˆ˜μ˜)은 올 2λΆ„κΈ° μ—°κ²° μž¬λ¬΄μ œν‘œ κΈ°μ€€ λ§€μΆœμ•‘ 2,127얡원, μ˜μ—…μ΄μ΅ 253얡원, λ‹ΉκΈ°μˆœμ΄μ΅ 115얡원을 κΈ°λ‘ν–ˆλ‹€κ³  14일 λ°ν˜”λ‹€. μ΄λŠ” μ „λ…„ 동기 λŒ€λΉ„ 각각 +1.4%, -16.9%, -50.0% μ¦κ°ν•œ μˆ˜μΉ˜λ‹€.μ—°κ²°μž¬λ¬΄μ œν‘œ κΈ°μ€€ λ§€μΆœμ•‘μ€ μ „λ…„ 동기 λŒ€λΉ„ μ¦κ°€ν•˜λ©° μ—­λŒ€ μ΅œλŒ€ λΆ„κΈ° 싀적을 κΈ°λ‘ν–ˆλ‹€. κ΅­λ‚΄ λ³΄νˆ΄λ¦¬λˆ” 톑신 μ‹œμž₯ 경쟁이 μ‹¬ν™”λ˜λ©° νœ΄λ©”λ”•μŠ€μ™€ νœ΄μ˜¨μŠ€λ°”μ΄μ˜€νŒŒλ§ˆ λ“± μ—μŠ€ν…Œν‹± μžνšŒμ‚¬ 싀적이 λ‘”ν™”λœ 영ν–₯ λ“±μœΌλ‘œ μ˜μ—…μ΄μ΅μ€ μ€„μ—ˆλ‹€.미래 μ„±μž₯ 동λ ₯을 ν™•λ³΄ν•˜κΈ° μœ„ν•œ μ—°κ΅¬κ°œλ°œ(R&D) λΉ„μš©μ΄ μ¦κ°€ν•œ

νœ΄μ˜¨μŠ€κΈ€λ‘œλ²Œμ΄ 올 2λΆ„κΈ° μ—°κ²° μž¬λ¬΄μ œν‘œ κΈ°μ€€ λ§€μΆœμ•‘ 2127얡원, μ˜μ—…μ΄μ΅ 253얡원, λ‹ΉκΈ°μˆœμ΄μ΅ 115얡원을 κΈ°λ‘ν–ˆλ‹€κ³  14일 λ°ν˜”λ‹€. μ „λ…„ 동기 λŒ€λΉ„ λ§€μΆœμ•‘μ€ 1.4% μ¦κ°€ν–ˆμ§€λ§Œ μ˜μ—…μ΄μ΅κ³Ό λ‹ΉκΈ°μˆœμ΄μ΅μ€ 각각 16.9%, 50% κ°μ†Œν–ˆλ‹€. νœ΄μ˜¨μŠ€κΈ€λ‘œλ²Œμ— λ”°λ₯΄λ©΄ μ—°κ²°μž¬λ¬΄μ œν‘œ κΈ°μ€€ λ§€μΆœμ•‘μ€ μ „λ…„ 동기 λŒ€λΉ„ μ¦κ°€ν•˜λ©° μ—­λŒ€ μ΅œλŒ€ λΆ„κΈ° 싀적을 κΈ°λ‘ν–ˆλ‹€. λ‹€λ§Œ κ΅­λ‚΄ λ³΄νˆ΄λ¦¬λˆ” 톑신 μ‹œμž₯ 경쟁이 μΉ˜μ—΄ν•΄μ§€λ©΄μ„œ νœ΄λ©”λ”•μŠ€μ™€ νœ΄μ˜¨μŠ€λ°”μ΄μ˜€νŒŒλ§ˆ λ“± μžνšŒμ‚¬ 싀적이 λ‘”ν™”ν–ˆκ³  μ˜μ—…μ΄μ΅μ΄ μ€„μ—ˆλ‹€. 미래 μ„±μž₯ 동λ ₯을 ν™•λ³΄ν•˜κΈ° μœ„ν•œ μ—°κ΅¬κ°œλ°œ(R&D) λΉ„μš©...

팬젠 맀좜 정보

λ‚ μ§œ λ§€μΆœμ•‘ λ§€μΆœμ•‘ μ¦κ°€μœ¨ μ˜μ—…μ΄μ΅ μ˜μ—…μ΄μ΅ μ¦κ°€μœ¨ 순이읡 순이읡 μ¦κ°€μœ¨
2024.4Q 14,672,686,810 100.58% 1,020,165,959 124.14% 943,686,868 121.02%
2023.4Q 7,315,125,370 12.53% -4,225,497,054 7.95% -4,488,830,770 0.11%
2022.4Q 6,500,658,000 -18.08% -4,590,629,400 -39.60% -4,493,832,000 -35.75%
2021.4Q 7,935,565,000 28.18% -3,288,356,900 11.13% -3,310,318,300 24.01%

μˆœλ§€μˆ˜λŸ‰

개인: 368

κΈ°κ΄€: 0

외인: -368

λˆ„μ  μˆœλ§€μˆ˜λŸ‰

개인: 2,331

κΈ°κ΄€: 0

외인: 6,336

순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-08-29 368 - -368
2025-08-28 -3,795 - 1,295
2025-08-27 -5,386 - 5,386
2025-08-26 240 - -240
2025-08-25 -2,017 - 2,017
2025-08-22 3,182 - -3,182
2025-08-21 2,832 - -2,315
2025-08-20 1,674 - -1,674
2025-08-19 1,030 - -1,548
2025-08-18 5,251 - -5,584
2025-08-14 2,007 - -2,507
2025-08-13 693 - -298
2025-08-12 41 - -41
2025-08-11 4,844 - -5,405
2025-08-08 1,318 - -1,318
2025-08-07 3,144 - -2,170
2025-08-06 -2,209 - 1,709
2025-08-05 -5,266 - 5,266
2025-08-04 -3,704 - 3,704
2025-08-01 16,500 - -16,666
2025-07-31 3,122 - -4,610

λˆ„μ  순맀수

λ‚ μ§œ 개인 κΈ°κ΄€ 외인
2025-08-29 23,869 - -28,549
2025-08-28 23,501 - -28,181
2025-08-27 27,296 - -29,476
2025-08-26 32,682 - -34,862
2025-08-25 32,442 - -34,622
2025-08-22 34,459 - -36,639
2025-08-21 31,277 - -33,457
2025-08-20 28,445 - -31,142
2025-08-19 26,771 - -29,468
2025-08-18 25,741 - -27,920
2025-08-14 20,490 - -22,336
2025-08-13 18,483 - -19,829
2025-08-12 17,790 - -19,531
2025-08-11 17,749 - -19,490
2025-08-08 12,905 - -14,085
2025-08-07 11,587 - -12,767
2025-08-06 8,443 - -10,597
2025-08-05 10,652 - -12,306
2025-08-04 15,918 - -17,572
2025-08-01 19,622 - -21,276
2025-07-31 3,122 - -4,610

팬젠 μžμ‚° λΉ„μœ¨

μžμ‚°μ΄κ³„ λΆ€μ±„λΉ„μœ¨ μžλ³ΈλΉ„μœ¨
36,882,873,829 20.03% 79.97%

팬젠 맀좜 ꡬ성

ꡬ성 μš”μ†Œ λΉ„μœ¨
λ°”μ΄μ˜€μ‹œλ°€λŸ¬ EPO [EPOμ˜μ•½ν’ˆ] 46.6%
μœ„νƒμƒμ‚°(CMO) 21.8%
기타 13.3%
κΈ°μˆ μ΄μ „(CDO) 13.2%
λ‘œμ—΄ν‹° 3.7%
μƒν’ˆ 1.4%

팬젠 곡맀도 ν˜„ν™©

졜근 곡맀도 κ±°λž˜λŸ‰: 1,106 (7.99%)

졜근 곡맀도 μž”κ³ : 0 (0%)

곡맀도 κ±°λž˜λŸ‰

λ‚ μ§œ μ’…κ°€ κ³΅λ§€λ„λŸ‰ 곡맀도비쀑
2025-08-29 6,050 1,106 7.99%
2025-08-28 5,980 675 4.27%
2025-08-27 6,040 316 2.57%
2025-08-26 5,950 598 9.74%
2025-08-25 5,950 496 5.03%
2025-08-22 5,980 782 7.21%
2025-08-21 5,940 1,505 12.39%
2025-08-20 5,710 697 4.04%
2025-08-19 5,730 1,484 10.22%
2025-08-18 5,810 1,349 7.35%
2025-08-14 6,070 1,801 14.69%
2025-08-13 5,970 2,055 7.73%
2025-08-12 6,060 861 7.14%
2025-08-11 5,960 2,932 11.71%
2025-08-08 6,220 1,478 8.29%
2025-08-07 6,150 1,411 12.27%
2025-08-06 6,170 1,715 7.39%
2025-08-05 6,050 884 3.92%
2025-08-04 6,120 884 4.43%
2025-08-01 6,100 3,676 6.44%
2025-07-31 6,530 615 3.50%

곡맀도 μž”κ³ 

λ‚ μ§œ μ’…κ°€ 곡맀도 μž”κ³  곡맀도 비쀑
2025-08-27 6,040 0 0.00%
2025-08-26 5,950 0 0.00%
2025-08-25 5,950 0 0.00%
2025-08-22 5,980 0 0.00%
2025-08-21 5,940 0 0.00%
2025-08-20 5,710 0 0.00%
2025-08-19 5,730 0 0.00%
2025-08-18 5,810 0 0.00%
2025-08-14 6,070 0 0.00%
2025-08-13 5,970 0 0.00%
2025-08-12 6,060 0 0.00%
2025-08-11 5,960 0 0.00%
2025-08-08 6,220 0 0.00%
2025-08-07 6,150 0 0.00%
2025-08-06 6,170 0 0.00%
2025-08-05 6,050 0 0.00%
2025-08-04 6,120 0 0.00%
2025-08-01 6,100 0 0.00%
2025-07-31 6,530 0 0.00%
2025-07-30 6,420 0 0.00%
2025-07-29 6,670 0 0.00%

팬젠 μ—…μ’… λ‚΄ 비ꡐ

생λͺ…κ³Όν•™/곡학 μ—…μ’…(90개) μ—°κ°„ κΈ°μ€€

ν•­λͺ© 팬젠 μ—…μ’… 평균 μ—…μ’… λ‚΄ μˆœμœ„
μ‹œκ°€μ΄μ•‘ 806.953 8,337.69 58μœ„
PER(졜근4λΆ„κΈ°) 32.121 724.29 10μœ„
PBR 2.736 15.5 50μœ„
ROE(졜근4λΆ„κΈ°) 5.036 -33.71 19μœ„
λ°°λ‹Ήμˆ˜μ΅λ₯ (μ΅œκ·Όμ—°λ„) - - -μœ„
μ˜μ—…μ΄μ΅λ₯ (μ΅œκ·Όμ—°λ„) 6.953 -1,735.95 15μœ„
순이읡λ₯ (μ΅œκ·Όμ—°λ„) 6.432 -1,637.93 19μœ„
λΆ€μ±„λΉ„μœ¨(μ΅œκ·Όμ—°λ„) 22.626 77.85 63μœ„
λ§€μΆœμ•‘(μ΅œκ·Όμ—°λ„) 146.727 483.11 33μœ„
μ˜μ—…μ΄μ΅(μ΅œκ·Όμ—°λ„) 10.202 -85.51 16μœ„
λ‹ΉκΈ°μˆœμ΄μ΅(μ΅œκ·Όμ—°λ„) 9.437 -70.67 23μœ„